CervoMed (CRVO) Research & Development (2014 - 2026)
CervoMed (CRVO) posted Research & Development of $5.1 million for Q1 2026, down 11.92% sequentially from $5.8 million in Q4 2025, and up 6.15% YoY from $4.8 million in Q1 2025.
CervoMed (CRVO) Research & Development (2014 - 2026) Analysis & Trends
CervoMed has reported Research & Development for 13 years, with the latest figure at $5.1 million in Q1 2026.
- Quarterly Research & Development rose 6.15% year-over-year to $5.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.1 million (up 6.21% YoY) and the FY2025 annual result came in at $21.8 million, up 16.06% from the prior year.
- Research & Development fell to $5.1 million in Q1 2026 per CRVO's latest filing, from $5.8 million in the prior quarter.
- Over five years, Research & Development peaked at $7.1 million in Q4 2024 and troughed at $330543.0 in Q3 2022.
- A 5-year average of $3.5 million and a median of $2.9 million in 2023 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2023: Research & Development plunged 84.3% in 2022, then surged 650.06% in 2023.
- Over 5 years, Research & Development stood at $380685.0 in 2022, then soared by 650.06% to $2.9 million in 2023, then jumped by 148.19% to $7.1 million in 2024, then decreased by 17.73% to $5.8 million in 2025, then fell by 11.92% to $5.1 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $5.1 million, $5.8 million, and $6.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.95 Bn | 132.10 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.71 Bn | 60.52 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 60.45 Bn | 55.31 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.24 Bn | 37.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.64 Bn | 10.25 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 97.90 Mn |
| 10 | CervoMed | 26.79 Mn | 26.79 Mn | - | 4.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.32 Mn |
| Mar 31, 2026 | 5.14 Mn |
| Dec 31, 2025 | 5.83 Mn |
| Sep 30, 2025 | 6.04 Mn |
| Jun 30, 2025 | 5.11 Mn |
| Mar 31, 2025 | 4.84 Mn |
| Dec 31, 2024 | 7.09 Mn |
| Sep 30, 2024 | 5.13 Mn |
| Jun 30, 2024 | 3.77 Mn |
| Mar 31, 2024 | 2.81 Mn |
| Dec 31, 2023 | 2.86 Mn |
| Sep 30, 2023 | 1.79 Mn |
| Jun 30, 2023 | 1.96 Mn |
| Mar 31, 2023 | 1.83 Mn |
| Dec 31, 2022 | 380,685.00 |
| Sep 30, 2022 | 330,543.00 |
| Jun 30, 2022 | 2.11 Mn |
| Mar 31, 2022 | 2.43 Mn |
| Dec 31, 2021 | 1.50 Mn |
| Sep 30, 2021 | 2.11 Mn |